Diabetes epidemiology and management最新文献

{"title":"The impact of diabetes on sarcopenia in community-dwelling older adults in India: key findings from the longitudinal ageing study in India (LASI)","authors":"Sayani Das","doi":"10.1016/j.deman.2023.100158","DOIUrl":"10.1016/j.deman.2023.100158","url":null,"abstract":"<div><h3>Background</h3><p>Diabetes has become a major public health issue in India, and understanding its impact on skeletal muscle health is crucial for addressing the elevated risk of sarcopenia among individuals with diabetes. While the association between diabetes and sarcopenia has been extensively studied worldwide, there is a notable lack of research focusing on this relationship within the Indian community-dwelling geriatric population. Therefore, this study aimed to explore the influence of diabetes on sarcopenia among older adults living in community settings in India.</p></div><div><h3>Methodology</h3><p>The study used data from the Longitudinal Aging Study in India (LASI), Wave 1 (2017–18). It was focused on older adults aged 60 years and above living in community settings in India, including both males and females. This study followed the Asian Working Group on Sarcopenia (2019) guidelines, utilizing a screening tool that assessed sarcopenia through muscle (handgrip) strength, physical performance, and appendicular skeletal muscle mass (ASM). The presence of diabetes was determined through a self-reported approach, where participants disclosed their diabetes diagnosis as provided by healthcare professionals. To examine the association between diabetes and sarcopenia, the study utilized logistic regression analysis to calculate the adjusted odds ratio (AOR) and corresponding 95% confidence interval (CI).</p></div><div><h3>Results</h3><p>Present study included 27,241 individuals, with sarcopenia prevalent in 27.0% of participants. 3.4% had both sarcopenia and diabetes, 23.5% had sarcopenia only, 11.7% had diabetes only, and 61.3% had neither. After adjusting for confounding variables, participants with diabetes had a significantly higher odds ratio of 1.14 (95% CI 1.06–1.26, <em>p</em> &lt; 0.001) for sarcopenia.</p></div><div><h3>Conclusions</h3><p>The study established that diabetes is a risk factor for sarcopenia in older adults living in India. Early identification and management are essential to mitigate sarcopenia, emphasizing the importance of addressing both conditions in healthcare.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48735290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrinologists’ use of patient-reported outcome measures in the care of people with diabetes: A qualitative study","authors":"B.K. Nielsen ,&nbsp;M.D. Terkildsen ,&nbsp;A.L. Jensen ,&nbsp;M.Z. Pedersen ,&nbsp;M.R. Hollesen ,&nbsp;K. Lomborg","doi":"10.1016/j.deman.2023.100159","DOIUrl":"10.1016/j.deman.2023.100159","url":null,"abstract":"<div><h3>Aims</h3><p>DiabetesFlex Care is a patient-reported outcome (PRO)-based telehealth service for adults with type 1 diabetes, intended to enable patient perspectives in consultations. The study aimed to explore endocrinologists' experiences of using PRO to support dialog in diabetes consultations.</p></div><div><h3>Methods</h3><p>Thematic analysis was conducted on data from participant observations and semi-structured interviews with 13 endocrinologists engaging in DiabetesFlex consultations at a Danish hospital-based diabetes clinic.</p></div><div><h3>Results</h3><p>Two themes were extracted: 'Perceiving PRO as ambiguous information' and 'Integrating PRO in the care for people with diabetes'. Endocrinologists perceived PRO as situational information with variable quality and validity, depending on patient competencies and commitment. Therefore, endocrinologists used different approaches to integrate PRO in their efforts to improve care for the individual patient. The study also showed that patients’ PRO-responses were rarely discussed among endocrinologists.</p></div><div><h3>Conclusion</h3><p>Endocrinologists experienced both potentials and challenges in using PRO to support diabetes consultations. To optimize DiabetesFlex Care and similar PRO-based diabetes consultations, a culture should be built up where clinicians share experiences to improve the quality and solve PRO-related problems in consultations.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43191252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of people with optimally-managed type 1 diabetes","authors":"Gijsbert Stoet ,&nbsp;Richard IG Holt","doi":"10.1016/j.deman.2023.100153","DOIUrl":"10.1016/j.deman.2023.100153","url":null,"abstract":"<div><h3>Objective</h3><p>The aim is to describe the characteristics of people with type 1 diabetes who are meeting all seven glycemic targets set by international consensus.</p></div><div><h3>Research Design &amp; Methods</h3><p>We analyzed continuous glucose monitoring (CGM) data from 497 participants (aged 18-70 yrs). Time-in-range, time above and below range, co-efficient of variability, and glucose management indicator (GMI) were combined with demographic data, insulin delivery, and exercise.</p></div><div><h3>Results</h3><p>While 68% of participants achieved a GMI below 7% (53 mmol/mol), 39% met all seven glycemic targets. Older people and those of White ethnicity were more likely to meet these targets. Men and women were equally likely to meet all targets, although men were more likely to experience hypoglycemia while women were more likely to experience hyperglycemia. Hybrid-closed loop (HCL) system users were more likely to meet all targets than people using a standard pump or multiple daily injections.</p></div><div><h3>Conclusions</h3><p>Only 56% of those with a GMI below 7% (53 mmol/mol) met all seven targets, illustrating how glycemic management involves more than GMI/HbA_1c lowering alone, which has implications for estimates of optimally managed participants in the wider population of people with type 1 diabetes. Demographic inequalities were prevalent. Using a HCL system clearly facilitated the achievement of glycemic targets.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43923721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic consequences of alterations in gut microbiota induced by antidiabetic medications","authors":"Venkata Chaithanya ,&nbsp;Janardanan Kumar ,&nbsp;Kakithakara Vajravelu Leela ,&nbsp;Matcha Angelin ,&nbsp;Abhishek Satheesan ,&nbsp;Ria Murugesan","doi":"10.1016/j.deman.2023.100180","DOIUrl":"https://doi.org/10.1016/j.deman.2023.100180","url":null,"abstract":"<div><p>The mutualistic relationship between human health and gut microbiota has gained growing attention as a result of its far-reaching consequences. Diabetes medications, essential for managing type 2 diabetes, which regulate glucose metabolism, have shown effects that go beyond glycemic control by receiving attention for their possible influence on gut microbiota. Notably, metformin, a cornerstone therapy, has received a lot of attention for its ability to influence the gut microbiota. Metformin administration has been linked to changes in the abundance of specific bacterial taxa, including an uprise in beneficial microbes like <em>Akkermansia muciniphila</em>. These modifications have been linked to increased insulin sensitivity and better metabolic outcomes. Other classes of diabetes drugs, in addition to metformin, have shown potential effects on the gut microbiota. SGLT-2 inhibitors, for example, may contribute to changes in gut microbial communities, which could explain their cardiovascular and metabolic benefits. However, the processes underlying these interactions, are complicated and not entirely understood. Direct interactions between the gut microbiota and drug, changes in intestinal permeability, and modulation of bile acid metabolism are all possible mechanisms. Individual differences and genetic factors complicate the relationship even more. Understanding the intricate interplay between diabetes drugs and gut microbiota holds promise for developing personalized diabetes management approaches. Taking advantage of these interactions could lead to novel therapeutic strategies that improve drug efficacy and overall metabolic health. More studies are required to determine the exact mechanisms underlying these effects and to capitalize on their potential for improved patient outcomes. This review provides a concise overview of the effects of diabetes medications on gut microbiota composition and its importance.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666970623000598/pdfft?md5=a6f9c3f9c66218d87de1a61a5edc4f00&pid=1-s2.0-S2666970623000598-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92096551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes","authors":"André J. Scheen","doi":"10.1016/j.deman.2023.100179","DOIUrl":"https://doi.org/10.1016/j.deman.2023.100179","url":null,"abstract":"<div><h3>Background</h3><p>Stroke represents a major burden in patients with type 2 diabetes. Yet, this cerebrovascular complication has been less well studied than coronary artery disease and heart failure. Some cardiovascular outcome data suggested that sodium-glucose cotransporter 2 inhibitors (SGLT2is) exert a less pronounced protection against stroke compared with glucagon peptide-1 receptor agonists (GLP-1RAs) despite similar efficacy regarding major cardiovascular events (MACE-3 points). However, this conclusion was derived from indirect comparisons of placebo- controlled trials (RCTs).</p></div><div><h3>Methods</h3><p>The present comprehensive review analyses the effects of SGLT2is versus GLP-1RAs on nonfatal and fatal/nonfatal strokes in real-life studies carried out worldwide.</p></div><div><h3>Results</h3><p>A large majority of retrospective observational cohort studies (19 out of 21) failed to find any significant difference in the risk of stroke between the two pharmacological classes, independently of the presence of established cardiovascular disease. Available, yet limited, findings suggested that SGLT2is could be more efficacious against haemorrhagic than ischaemic strokes, in patients at risk for atrial fibrillation or with chronic kidney disease.</p></div><div><h3>Conclusion</h3><p>In contrast to what was reported in RCTs, most observational studies showed similar incidence of stroke in SGLT2i users versus GLP-1RA users. Because both indirect comparisons of RCTs and retrospective cohort studies have limitations, a head-to-head RCT comparing the effects on stroke of an SGLT2i versus a GLP-1RA is needed to draw any definite conclusion.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67739978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 for type 2 diabetes in insulin naive patients: a systemic review and meta-analysis","authors":"Faiza Zakaria, Ahmed Kunwer Naveed, Mushood Ahmed, Rameen Rao, Areeba Shaikh, Anusha Abdul Muqeet Farid, Tehreem Ali, Muhammad Hasanain","doi":"10.1016/j.deman.2023.100181","DOIUrl":"https://doi.org/10.1016/j.deman.2023.100181","url":null,"abstract":": Insulin Therapy is essential for managing diabetes, but difficulties such as daily injections and hypoglycemia risk hinder patient compliance. Recent advancements have brought basal insulin analogs such as insulin icodec and insulin glargine U100 so in this study we aimed to assess the efficacy and safety of Once-Weekly Insulin icodec and Once-Daily insulin glargine-U100 in Insulin-Naive type 2 diabetic patients (T2DM). : The PRISMA guidelines were followed in conducting this meta-analysis. An electronic search was conducted utilizing databases such as PubMed, Google Scholar, OvidSP, and the Cochrane Database of Controlled Studies (CENTRAL). The analysis findings were combined using a random-effects model. Continuous outcomes were expressed as mean difference (MD), whereas dichotomous outcomes were represented as odds ratios (ORs) with 95% confidence intervals (95% CIs). : 3 randomized control trials (RCTs) comprising 1436 patients were included in our analysis. Pooled analysis showed a significant difference in improved time with glucose range (%TIR) between icodec group and glargine U100 (MD=4.89; 95% CI= 2.95 to 6.82; P=<0.00001; I2=0%), reduction in HbA1c (MD=-0.19; 95% CI= -0.30 to -0.08; P=0.0009; I2=0%), risk of hypoglycemia alert (OR=1.47; 95% CI=1.18-1.84; P=0.0006; I2=0%). There was no significant difference in pooled analysis for fasting plasma glucose levels, severe hypoglycemia, and any adverse effects or hyperactivity events. : Our systematic review and meta-analysis provided evidence that favored Once-Weekly Insulin Icodec over Once-Daily Insulin Glargine U100 for patients with T2DM.","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135389060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoglycemia avoidance behaviour in active Qatari adults with type 1 diabetes under blood glucose monitoring device","authors":"Georges Jabbour,&nbsp;Souhail Hermassi","doi":"10.1016/j.deman.2023.100176","DOIUrl":"10.1016/j.deman.2023.100176","url":null,"abstract":"<div><h3>Aims</h3><p>The present study aimed to explore the relationship between fear of hypoglycemia and exercise management strategies in active Qatari adults with T1D during the COVID-19 pandemic, and to explore the potential role of continuous glucose monitoring (CGM) devices in promoting safe physical activity practices.</p></div><div><h3>Methods</h3><p>Participants completed the Hypoglycemia Fear Survey (HFS) questionnaire and the International Physical Activity Questionnaire (IPAQ). Out of the 102 participants, 41 were considered \"active\" and under CGM and were included in the analysis.</p></div><div><h3>Results</h3><p>Multiple linear regression analysis revealed a significant positive correlation between the behavior dimension of the HFS scores and both vigorous physical activity and MET-minutes per week (<em>R</em>² adj. = 0.055; β = 0.56; <em>p</em> = 0.05 and <em>R</em>² adj. = 0.039; β = 0.38; <em>p</em> = 0.04). The results showed a significant positive association between HbA1c levels and the behavior dimension of the HFS (<em>R</em> = 0.39, <em>p</em> = 0.005), as well as between the number of episodes of severe hypoglycemia and the behavior dimension (<em>R</em> = 0.46, <em>p</em> = 0.042).</p></div><div><h3>Conclusion</h3><p>These findings highlight the need for effective strategies to manage fear of hypoglycemia and promote physical activity in individuals with T1D. The use of CGM devices may provide added safety to physical activity practices by reducing the risk of hypoglycemia.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44817312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of lowered level of serum vitamin D on diabetic foot ulcer and its possible pathomechanism: A systematic review, meta-analysis, and meta-regression","authors":"Muhammad Iqhrammullah ,&nbsp;Teuku Fais Duta ,&nbsp;Meulu Alina ,&nbsp;Intan Qanita ,&nbsp;Muhammad Alif Naufal ,&nbsp;Najlaika Henira ,&nbsp;Ghina Tsurayya ,&nbsp;Raisha Fathima ,&nbsp;Arita Yuda Katiara Rizki ,&nbsp;Shakira Amirah","doi":"10.1016/j.deman.2023.100175","DOIUrl":"10.1016/j.deman.2023.100175","url":null,"abstract":"<div><h3>Aim</h3><p>To investigate the association between serum vitamin D (SVD) level and DFU development and to emphasize the involved pathomechanism.</p></div><div><h3>Methods</h3><p>The search was performed on 12 databases for literature published until 10 March 2023. The protocol has been registered on PROSPERO (CRD42023415744). The selection for the included records followed PRISMA framework. Meta-analyses using random effects model were performed and the data were presented as SMD and 95% CI. Meta-regression was performed to identify factors contributing to the heterogeneity in the pooled analysis.</p></div><div><h3>Results</h3><p>Twenty-one studies were included in the systematic review with a total number of patients reaching 9,570. Of which, as many as 18 studies were eligible for the meta-analysis. The SDV level is significantly lower in DFU group (<em>p</em>-total=0.0037; SMD= -1.2758; [95% CI: -2.0786 to -0.4730]). Based on the meta-regression, age, study location (based on the continent), and total cholesterol level contribute to the high heterogeneity (<em>p</em>&lt;0.01). In the pooled analysis, inflammatory markers such as serum levels of CRP (<em>n</em> = 4), ESR (<em>n</em> = 3), IL-6 (<em>n</em> = 3), and IL-8 (<em>n</em> = 2) are found significantly higher in DFU group at <em>p</em>&lt;0.01.</p></div><div><h3>Conclusion</h3><p>Lowered SVD level is associated with DFU, where the pathomechanism for this relationship might involve inflammation and infection susceptibility.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666970623000549/pdfft?md5=a793bb5ca98f0b390dd67ecff08899f0&pid=1-s2.0-S2666970623000549-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47167251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-rich plasma (PRP) as therapy for diabetic foot ulcer (DFU): A systematic review and meta-analysis of the latest randomized controlled trials","authors":"Fara Syafira ,&nbsp;Muhammad Baharul Iman ,&nbsp;Pariyana ,&nbsp;Rita Sriwulandari","doi":"10.1016/j.deman.2023.100178","DOIUrl":"10.1016/j.deman.2023.100178","url":null,"abstract":"<div><h3>Objectives</h3><p>Diabetic foot ulcer (DFU) is a prevalent and serious complication of diabetes, associated with significant morbidity and mortality rates. Platelet-rich plasma (PRP) is a promising therapy for accelerating DFU healing, with numerous randomized controlled trials (RCTs) supporting its efficacy and safety. Therefore, this systematic review aims to identify, critically assess, and synthesize the most recent available RCTs regarding the effectiveness of clinical PRP for treating DFU compared to standard treatment or other alternative therapies.</p></div><div><h3>Methods</h3><p>This study uses a comprehensive review and synthesis of existing research according to the 2020 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We searched selected databases using a combination of search terms: “((PRP) OR (\"platelet-rich plasma\")) AND (\"diabetic foot ulcer\")) OR (\"diabetic lower-extremity ulcer\"))” from PubMed, ProQuest, ScienceDirect, and Google Scholar in the last five years (2018–2023). Following a systematic review protocol, we selected 9 eligible articles for final analysis. Pertinent data was examined using MedCalc ver 20.215 then the results were displayed visually using forest plots.</p></div><div><h3>Results</h3><p>The findings from the meta-analysis revealed that PRP exhibited a healing rate that was twice as high as the control group (Relative Effects (REs) = 2.338; 95% Confidence Interval (CI) = 1.056 to 1.857, <em>P</em> = 0.019). Additionally, the healing time was shortened by 2 days (REs = -2.815; 95% CI = -3.252 to -0.576, <em>P</em> = 0.005), and there was a difference of 0.482 cm² in the reduction of ulcer area between the two groups (REs = 0.482; 95% CI = -2.428 to 4.002, <em>P</em> = 0.630). Importantly, none of the Randomized Controlled Trials (RCT) studies reported any adverse events in the PRP group.</p></div><div><h3>Conclusions</h3><p>PRP represents a feasible and secure supplementary therapeutic alternative for managing DFU.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666970623000574/pdfft?md5=1ee81b675261c67273496cc19986f9a2&pid=1-s2.0-S2666970623000574-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47333016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of the burden of diabetes among adults and children in Québec, Canada, from 2001 to 2019: A population-based longitudinal surveillance study","authors":"Sarah O'Connor ,&nbsp;Philippe Robert ,&nbsp;Jacinthe Leclerc ,&nbsp;Paul Poirier ,&nbsp;Marjolaine Dubé ,&nbsp;Pierre-Luc Trépanier ,&nbsp;Linda Perron ,&nbsp;Claudia Blais","doi":"10.1016/j.deman.2023.100177","DOIUrl":"10.1016/j.deman.2023.100177","url":null,"abstract":"<div><h3>Introduction</h3><p>Many developed countries, including Canada, have observed reductions in incidence of diabetes. Given the latest improvements in the case definition of diabetes for the younger population in Quebec, Canada, we sought to examine the evolution of diabetes among adults and children in Quebec, between 2001 and 2019.</p></div><div><h3>Methods</h3><p>Crude and age-standardized incidence and prevalence of diabetes among individuals ≥1 year were calculated using data from the Quebec Integrated Chronic Disease Surveillance System (n≈8,351,500 in 2019), using two case definitions for adults and the youth respectively. Age-standardized all-cause hospitalizations and mortality proportions were calculated among the population ≥20 years.</p></div><div><h3>Results</h3><p>Between 2001 and 2019, age-standardized incidence decreased by 30%, with a crude incidence of 4.6 per 1,000 in 2019. Incidence rates decreased from age group ≥50 years but increased by 25% for the group of 1-19 years. Age-standardized prevalence increased by 42% (crude prevalence in 2019: 8.1%). Males had higher incidence and prevalence of diabetes, with an incremental gap between sexes increasing with age. All-cause hospitalization and mortality proportions among individuals with diabetes declined by 21% and 29% respectively between 2001 and 2019. Age-standardized hospitalizations and mortality ratios for individuals with/without diabetes remained stable and were 2.7 (99% Confidence Intervals [CI]: 2.7-2.8) and 2.2 (99% CI: 2.1-2.3) in 2019, respectively.</p></div><div><h3>Conclusion</h3><p>Despite the reduction of incidence among adults, diabetes incidence increased among the youth and remained high among adults, especially for males. These results highlight the importance of improving earlier preventive care and initiatives for reducing the diabetes burden in Quebec.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41367649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}